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Background: Neurological complications after cardiac surgery have a profound impact on postoperative survival
and quality of life. The increasing importance of strategies designed to improve neurological outcomes mirrors the
growing risk burden of the contemporary cardiac surgical population. Remote ischemic preconditioning (RIPC)
reduces adverse sequelae of ischemia in vulnerable organs by subjecting tissues with high ischemic tolerance to
brief periods of hypoperfusion. This trial will evaluate the neuroprotective effect of RIPC in the cardiac surgical
arena, by employing magnetic resonance imaging (MRI) and neurocognitive testing.
Methods: Patients scheduled for elective coronary artery bypass grafting with the use of cardiopulmonary bypass
will be screened for the study. Eligible patients will be randomized to undergo either a validated RIPC protocol
or a sham procedure. The RIPC will be induced by inflation of a blood pressure cuff to 200 mmHg for 5 minutes,
followed by a 5-minute reperfusion period. Three sequences of interchanging cuff inflations and deflations will be
employed. Neurocognitive testing and MRI imaging will be performed preoperatively and on postoperative day 7.
Paired pre- and postoperative neurocognitive and neuroimaging data will then be compared. The primary composite
outcome measure will consist of new ischemic lesions on brain MRI, postprocedural impairment in brain connectivity
on resting-state functional MRI (rs-fMRI), and significant new declines in neurocognitive performance. The secondary
endpoint measures will be the individual components of the primary endpoint measures, expressed as continuous
variables, troponin T release on postoperative day 1 and the incidence of major adverse cardiovascular events at
3 months postoperatively. Major adverse cardiovascular events, including accumulating cardiovascular mortality,
stroke, nonfatal myocardial infarction, and rehospitalization for ischemia, will form a composite endpoint measure.
Discussion: This trial will aim to assess whether RIPC in patients subjected to surgical myocardial revascularization
employing cardiopulmonary bypass initiates a neuroprotective response. Should the results of this trial indicate that
RIPC is effective in reducing the incidence of adverse neurological events in patients undergoing coronary artery
bypass grafting, it could impact on the current standard of care.
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Neurological impairment following coronary artery bypass
grafting may take on the form of stroke or postoperative
cognitive dysfunction. The former is rare, but potentially
devastating. However, a decline in attention, memory, or
fine motor skills can frequently be documented by sensi-
tive neurocognitive testing [1]. Postoperative deterioration
in neurocognitive capacity is often discrete, but exerts an
adverse impact on the quality of life. Its reversibility is
subject to interpatient variability, with 25% of patients still
exhibiting signs of cognitive impairment 6 months after
surgery [1,2].
Ischemic preconditioning exploits the endogenous
protective potential against sustained ischemia incurred
by brief episodes of ischemia and reperfusion [3]. The
phenomenon is probably triggered by both neuronal and
humoral pathways [3]. In an experimental setting, transfer
of coronary effluent from an ischemically preconditioned
rabbit to an ischemic-preconditioning-naïve animal reduced
myocardial infarct size in the latter [4]. This observation
consolidated the hypothesis of a humoral protective medi-
ator [4]. This hypothesis was corroborated by the induction
of protection in a denervated donor heart by limb ischemia
[5]. The fact that ischemic-preconditioning-induced organ
protection was inhibited by a ganglion blocker, however,
gave credence to the idea of the existence of underlying
neural pathways [3].
Remote ischemic preconditioning (RIPC) denotes the
concept by which brief episodes of sublethal ischemia in
tissues with high ischemic tolerance stimulate protection
in distant organs from a subsequent severe insult [6]. It is
conceptually much simpler to induce than conventional
ischemic preconditioning, thereby expanding its clinical
applicability. Several reports have demonstrated that RIPC
protocols lead to reductions in myocardial injury following
cardiac surgery [7,8]. Thielmann et al. [9] recently showed
that RIPC induced by upper limb ischemia in patients
undergoing elective coronary artery bypass grafting led to
a reduction in troponin T release, which mirrored an ob-
served reduction in mortality (ratio, 0.27; 95% confidence
interval, 0.08 to 0.98; P = 0.046).
The relative paucity of effective management options to
treat neurological dysfunctions once they have become
clinically manifest provides a strong impetus for defining
strategies that reduce their incidence [10]. Ischemic pre-
conditioning has been shown to induce ischemic tolerance
in the brain via key survival signaling pathways, which
promote synaptic and mitochondrial adaptations [11].
These modifications reduce the adverse impact of excito-
toxicity, which is pivotal to ischemic neuronal injury [11].
Ischemic preconditioning produces two windows of pro-
tection. The early window of protection follows rapidly
after the event that induced it [10], while delayed precon-
ditioning occurs after a 24-hour delay [10]. The latter isprotein synthesis-dependent, with subsequent protection
extending for up to 96 hours. The benefits of early pre-
conditioning are that it can be relied upon to promote
organ protection immediately prior to an index event
carrying a risk of brain injury [10]. In an experimental
model, RIPC has been found to exert a beneficial effect on
multiple variables acting as surrogate markers of brain
injury following prolonged circulatory arrest [12]. These
included a reduction in brain lactate release, a faster
recovery of electroencephalographic activity and superior
quantitative behavioral scores [12].
Magnetic resonance imaging (MRI) allows for sensitive
delineation of the anatomical substrate underlying ischemic
injury [13]. Its potential to detect clinically silent brain
injury has been clearly recognized [14]. Specifically, hyper-
intensity on diffusion-weighted imaging, together with a de-
crease in the apparent diffusion coefficient, is effective in
demarcating the core of acute ischemic lesions [13]. Com-
binations of different MRI signals provide complementary
information on the evolution of organic neuropathology
[13]. Resting-state functional MRI (rs-fMRI) is a novel
instrument that focuses on functional brain connectivity,
rather than attempting to define structural pathology [15];
it harbors the potential to identify the presence of anatom-
ically divergent regions that operate in synchrony as large-
scale neural networks [16]. These anatomically distributed
regions act in concert to determine a variety of complex
behavioral patterns.
In our study, coronary surgery using cardiopulmonary
bypass will be considered the index deleterious event.
The mechanisms of neurologic injury following cardio-
pulmonary bypass include ischemia, inflammation, cerebral
edema, and hyperthermia [1]. Brain ischemia occurring
during cardiac surgery might be the consequence of em-
bolic showers consistently shown on transcranial Doppler
during episodes of aortic manipulation, or procedure-
associated hypoperfusion [1,14].
Strategies designed to protect end-organ function are
paramount in current cardiac surgical practice. The con-
vergence of the ever-increasing patient-risk profile with
the growing complexity of modern cardiac surgical proce-
dures underscores the importance of defining algorithms
that will maintain acceptable clinical outcomes.
We hypothesized that the neuroprotective potential of
RIPC could translate into an improvement in neuro-
logical imaging or functional outcomes among cardiac
surgical patients.
Methods
Study population
The study is designed as a single-center, prospective,
randomized, double-blind controlled trial (Figure 1).
Adult patients with multivessel coronary disease under-
going primary, elective coronary artery bypass grafting at
Figure 1 Flowchart depicting the screening, recruitment and randomization algorithm. AMI, acute myocardial infarction; CABG, coronary
artery bypass grafting; LVEF, left ventricular ejection fraction; MACCE, major adverse cardiac and cerebrovascular event; MRI, magnetic resonance
imaging; NCT, neurocognitive testing, PVD, peripheral vascular disease; TIA, transitory ischemic attack.
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study enrollment. Following the process of primary tri-
age, they will be approached by a study nurse who will
provide detailed information about the trial. Written
informed consent will be obtained from all patients prior
to enrollment. Preoperative and postoperative exclusion
criteria are summarized in Table 1.
Ethics
The ethics committee of the University Hospital Center
Zagreb evaluated and approved the conduct of this study
(Registration No. 380-59-10106-13-195/292) in December2013. Ethical standards in line with the Declaration of
Helsinki involving research on human subjects will be
strictly adhered to. This protocol complies with CON-
SORT guidelines [17].
Sample size
The estimation of the approximate sample size for this
study was based on an exact sign (binomial) test, assuming
an effect size of 0.20. To account for potential postoperative
contraindications for MRI and study consent withdrawals,
an estimated 70 patients will be required to test the null
hypothesis with an α value of 0.05 and a power of 0.90 [18].
Table 1 Study inclusion and exclusion criteria
Inclusion criteria Rationale for inclusion
Adult patients (18 to 80 years) undergoing primary coronary artery
bypass grafting with the use of cardiopulmonary bypass
Population of interest
Preoperative exclusion criteria Rationale for exclusion
Emergent coronary artery bypass grafting Higher-risk profile
Recent acute myocardial infarction Concurrent indication for dual antiplatelet therapy
History of stroke or transitory ischemic attack Prior neurological condition
Structural brain abnormalities Prior neurological condition
Carotid artery disease Ineligible for study enrollment
Valve surgery Ineligible for study enrollment
Left ventricular ejection fraction <30% Higher-risk profile
Atrial fibrillation Higher-risk of neurological complications
Renal failure Higher-risk profile
Repeat coronary artery bypass grafting Higher-risk profile
Off-pump coronary artery bypass grafting Avoidance of cardiopulmonary bypass
Inability to provide consent Ineligible for study enrollment
Contraindications for MRI Ineligible for study enrollment
Peripheral vascular disease of upper extremities Contraindication for remote ischemic preconditioning
Postoperative exclusion criteria Rationale for exclusion
New-onset contraindication for MRI Protocol violation
Hemodynamic instability Inability to complete follow-up MRI
MRI, magnetic resonance imaging.
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Randomization will be based on computer generated cod-
ing. Codes will be kept in sealed envelopes. These will be
opened in the operating room by an anesthesiologist not
involved in subsequent data accumulation or analysis.
Patients randomized to the intervention arm will be
subjected to brief periods of upper limb ischemia designed
to induce RIPC, as described later. Patients assigned to
the control arm will receive no ischemic preconditioning.
Surgeons and intensive care physicians will be unaware of
treatment allocation.Intervention and control protocols
Remote ischemic preconditioning will be induced by alter-
nating periods of upper limb ischemia and reperfusion.
Transient arm ischemia will be produced by inflating a
blood pressure cuff to 200 mmHg for 5 min, and then
deflating it for 5 min. This sequence will be repeated three
times after the induction of anesthesia and prior to the
surgical incision. Our intervention protocol has been used
previously and constitutes a validated protocol with bene-
ficial effects exerted at the myocardial level [9]. Patients in
the control group will also have a blood pressure cuff
placed, but it will not undergo the aforementioned
inflation-and-deflation cycles.Myocardial revascularization
Morphine and diazepam will be administered to patients
preoperatively. Induction and maintenance of anesthesia
will rely on a combination of midazolam, sufentanil,
pancuronium bromide, and sevoflurane. Propofol will be
avoided, owing to its potential for inhibiting RIPC-
inducing pathways [9].
Coronary revascularization will be performed via a me-
dian sternotomy with the use of cardiopulmonary bypass.
Systemic heparinization with a target activated clotting
time >450 s will be utilized. Both distal coronary and
proximal anastomoses will be performed during a single
period of aortic cross-clamping, thereby reducing the em-
bolic burden related to aortic manipulation. Myocardial
protection will be based on administration of both ante-
grade and retrograde cardioplegia. In the immediate
period after cardiopulmonary bypass, a goal-oriented
strategy targeting a cardiac index of 2.2 l/(min m2) will be
employed. Interventions to attain this goal will include
optimization of preload and, if necessary, inotropic sup-
port. The preferred inotropic agent in our institution is
dobutamine. In the unlikely event that further escalation
of vasoactive support is required, our armamentarium also
includes phosphodiesterase 3 inhibitors, intra-aortic balloon
pumps, and mechanical circulatory assistance. Full heparin
reversal with protamine will be employed.
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Venous blood samples for the measurement of troponin T
will be taken on postoperative day 1. We will employ the
Elecsys® Troponin T high-sensitive assay (Roche, Basel,
Switzerland).
Perioperative management
Postoperative medications will typically include a beta-
blocker, a hydroxy-methyl-glutaryl-CoA reductase inhibi-
tor and a diuretic. Aspirin (300 mg) will be administered
within 6 hours of surgery, provided that the chest tube
output is minimal. The use of angiotensin-converting-
enzyme inhibitors postoperatively will be individualized
and tailored to effect. Peptic ulcer prophylaxis will be
universally implemented in the perioperative period, and
continued for six weeks.
Neurocognitive testing
Neurocognition in study patients will be evaluated using
the Montreal Cognitive Assessment and the Trail Making
Test. Neurocognitive testing will be performed preopera-
tively and on postoperative day 7. The Montreal Cognitive
Assessment is a screening instrument for mild cognitive
dysfunction, but it has also been used to assess cognitive
functions in various neurological disorders, such as stroke,
Parkinson’s disease, and multiple sclerosis [19-21]. It is
suitable for the assessment of both distributed and focal
cognitive domains, such as attention and concentration,
executive functions, memory, language, visuoconstruc-
tional skills, conceptual thinking, calculation, and orienta-
tion. While the maximum test result is 30 points, a score
of 26 is at the lower extreme of normal. As the patients in
this study will be screened twice in a short period of time,
we will use two versions of the test to negate the possible
influence of a learning curve. A validated Croatian-
language version is available for clinical and research pur-
poses [22]. The Trail Making Test is a commonly employed
neuropsychological instrument for evaluating visual atten-
tion, speed of processing and executive functioning [23]. It
consists of two separate tasks, which evaluate the subject’s
ability to alternate between cognitive categories [24]. In Part
A, the subject is required to link randomly assigned num-
bers in ascending order. The goal in Part B is to link alter-
nate numbers and letters in a pre-determined order (that is,
1-A-2-B…). The personnel responsible for neurocognitive
testing will be unaware of the individual patient’s allocation
to either the intervention or control arms.
Neuroimaging
A comprehensive set of MRI sequences will be used for
the analysis and quantification of structural and func-
tional brain impairment following a standardized cardiac
surgical procedure (Table 2). Patients with significant
structural abnormalities identified on preoperative brainMRI (such as hydrocephalus, neurodevelopmental disor-
ders, or brain tumors) will be excluded from the study.
Magnetic resonance imaging will be performed twice in
all patients (before cardiac surgery and on postoperative
day 7) on a 3 T MR scanner (Magnetom TrioTim;
Siemens, Munich, Germany) using a 32-channel head
coil. To detect new structural ischemic lesions, pre and
postoperative MRI exams will be compared for each
patient. Fluid attenuated inversion recovery sequences
(TR, 9000 ms; TE, 87 ms; voxel size, 0.9 × 0.9 × 4 mm,;
field of view, 230 × 183; matrix, 204 × 256; flip angle,
130°) will be used to detect ischemic lesions and
diffusion-weighted imaging sequences (TR, 3100 ms; TE,
92 ms; voxel size, 1.8 × 1.8 × 5 mm; field of view, 230 ×
230; matrix, 128 × 128; b1,= 0 s/mm2; b2, 500 s/mm2; b3,
1000 s/mm2), together with calculated apparent diffusion
coefficient maps, will be used to differentiate between old
and new ischemic lesions. Regions of diffusion-weighted
imaging hyperintensity and decreases in apparent diffu-
sion coefficient correlate with acute ischemic brain injury
[13], and will constitute a component of the primary end-
point measure. The volumes of new ischemic lesions will
be calculated using Analyze 8.1 software (Mayo Clinic,
Rochester, MN, USA). For rs-fMRI, gradient-echo echo-
planar imaging sequences sensitive for blood-oxygen level
dependent contrast will be applied (TR, 3000 ms; TE,
31 ms; voxel size, 3.4 × 3.4.3 mm; field of view, 220 × 220;
matrix, 64 × 64; flip angle, 90°) for a period of 10 minutes
and 8 seconds. Functional image data will be co-registered
with high-resolution magnetization-prepared rapid acqui-
sition gradient-echo T1 sequences (TR, 1900 ms; TE,
2.52 ms; voxel size, 1 × 1 × 1 mm; field of view, 250 × 250;
matrix, 246 × 256, flip angle, 9°). The advantage of rs-
fMRI lies in its ability to detect increases in the blood-
oxygen level dependent contrast, as a measure of neural
activity. Blood-oxygen level dependent signal variability is
a surrogate measure of integrated synaptic activity [16].
All preprocessing, quality assurance, structural, and func-
tional connectivity analyses will follow prior validated and
published approaches that have been applied to clinical
populations [25,26]. Briefly, we will perform the following
preprocessing steps for all blood-oxygen level dependent
images, as previously described [25,26]: (i) slice-time cor-
rection, (ii) first five images removed from each run, (iii)
rigid-body motion correction, (iv) 12-parameter affine
transform of the structural image to the Talairach coordinate
system, and (v) coregistration of volumes to the structural
image with 3 × 3 × 3 mm resampling.
In addition, all blood-oxygen level dependent images
will pass stringent quality assurance criteria to ensure
that all data were of high and comparable quality across
groups: (i) signal-to-noise ratios >100, computed by
obtaining the mean signal and standard deviation for a
given slice across the blood-oxygen level dependent run,
Table 2 Summary of the MRI neuroimaging portfolio
MRI imaging sequences Diagnostic target
T1, T2, proton density signal weighting Ischemic or hemorrhagic brain lesions.
Structural brain abnormalities (hydrocephalus, neurodevelopmental disorders, brain tumors).
Magnetization-prepared rapid acquisition
gradient-echo (three-dimensional)
Structural brain abnormalities.
Anatomical three-dimensional template for subsequent rs-fMRI coregistration.
Fluid attenuated inversion recovery Ischemic lesion of the brain parenchyma (acute, subacute, and chronic).
Diffusion-weighted imaging Discrimination between acute, subacute, and chronic ischemic lesions, based on reduced
diffusibility in acute or subacute lesions presenting as high signal on diffusion-weighted
imaging sequence and low signal on calculated apparent diffusion coefficient maps.
rs-fMRI Functional brain connectivity within neural networks. Comparison of functional connectivity
patterns before and after operation.
MRI, magnetic resonance imaging; rs-fMRI, resting-state functional magnetic resonance imaging.
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(ii) no blood-oxygen level dependent run with a single
frame movement greater than one functional voxel; (iii)
movement scrubbing [27,28]. Lastly, to remove potential
sources of spurious signal in resting-state data, additional
preprocessing steps will be completed, according to stand-
ard practice [29]: all blood-oxygen level dependent time-
series underwent high-pass (0.009 Hz) and low-pass
(0.08 Hz) temporal filtering, nuisance signal removal from
ventricles and deep white matter, global signal regression,
six rigid-body motion correction parameters, and first
derivatives using in-house MatLab tools [30].Outcome definitions
The primary composite outcome will consist of new
ischemic lesions on brain MRI, impairment in brain
connectivity on resting-state functional MRI (rs-fMRI) and
postoperative cognitive dysfunction. Postoperative cognitive
dysfunction will be defined as a decrease of at least one
standard deviation in at least two components of neurocog-
nitive testing.
The secondary endpoint measures will be:
1. Volumetric quantification of areas of new ischemic
lesions on structural brain MRI.
2. Changes between pre- and post-rs-fMRI, expressed
as continuous variables and compared among the
intervention and control arms.
3. Percentage declines in individual neurocognitive tests.
4. Troponin T release on postoperative day 1.
5. Incidence of major adverse cardiovascular events at
3 months postoperatively.
Major adverse cardiovascular events will comprise a
composite endpoint measure, consisting of cardiovascular
mortality, stroke, nonfatal myocardial infarction, and re-
hospitalization for ischemia. Perioperative myocardial in-
farction will be adjudicated in accordance to the definitionsupplied by the Joint European Society of Cardiology/
American College of Cardiology Foundation/American
Heart Association/World Heart Federation Task Force for
the Redefinition of Myocardial Infarction [31]. Briefly, a
troponin T value ten times the 99th percentile of the
upper reference limit, coupled with electrocardiogram
changes, new-onset coronary artery (or graft) occlusion,
or imaging evidence of new wall motion abnormalities will
meet the criteria for perioperative myocardial infarction
[31]. Stroke will be a defined on the basis of either a new
focal deficit lasting >24 hours or an imaging study sug-
gestive of a new lesion in patients with prompt neuro-
logical recovery [32].
Statistical analysis
The frequency distributions of primary and secondary study
endpoints will be compared across the groups using 2 × 2
contingency tables. Continuous data will be presented as
mean values ± standard deviation or medians with their re-
spective interquartile range. Categorical variables will be pre-
sented as absolute numbers with percentages. Measures of
association of categorical data will be derived from Fisher’s
exact test. Analysis of continuous data will rely on the
Mann-Whitney U test or Student’s t test. Comparisons of
functional connectivity between regions of interest on pre-
and postoperative rs-fMRI will be performed with the
Wilcoxon matched-pairs test. Correlations between multiple
variables of interest will be examined using Spearman’s or
Pearson’s correlation coefficients. The choice between para-
metric and nonparametric statistical tools will be based on
the normality of distribution. A two-tailed P value of less
than 0.05 will be considered significant for all deployed stat-
istical calculations. The data will be processed using the
IBM SPSS Statistics software package (version 20.0; Somers,
NY, USA).
Discussion
Alternating cycles of nonlethal ischemia and reperfusion
induce an endogenous response that renders tissues
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[3]. In contrast with ischemic preconditioning, which is
essentially restricted to the experimental arena, RIPC
has the capacity for translation into the clinical domain
[9]; it induces ischemic tolerance in distant organs by
provoking ischemia in tissues that are both easily accessible
and resistant to noxious stimuli. In this prospective ran-
domized trial, RIPC will be evaluated as a neuroprotective
strategy in the cardiac surgical arena. We believe that
the high frequency of discrete neurological dysfunction
following cardiac surgery, coupled with the proven benefit
of RIPC on the induction of ischemic tolerance in other or-
gans, constitutes a sound basis for this research. A strategy
that would increase ischemic tolerance within the ischemic
penumbra could potentially yield superior neurological
outcomes.
In this prospective randomized study, a homogenous
cardiac surgical patient population will be subjected to a
validated RIPC protocol. Previous research has focused on
the reduction of myocardial ischemic injury after cardiac
surgery induced by RIPC [1]. To the best of our know-
ledge, this is the first trial that will specifically address the
neuroprotective value of this strategy in patients undergo-
ing surgical myocardial revascularization. The comprehen-
sive battery of brain MRI tools that will be used, coupled
with neurocognitive testing, will allow for the identification
of discrete neurologic injuries, thereby increasing the trial’s
diagnostic sensitivity.
The etiology of brain injury following cardiac surgery
is multifaceted, and not all of its potential triggers can
be addressed in a single trial. Our study will focus on a
strategy hypothesized to reduce the impact of ischemia
on end-organ performance.
While the trial will enroll patients from the lower-risk
stratum of the contemporary cardiac surgical practice, the
fact that the pathophysiology of brain ischemia is no
different in higher-risk patients will allow for the results of
this trial to be generalized onto a wider surgical cohort.
Should the preoperative implementation of a RIPC proto-
col result in improvement in postoperative neurologic
outcomes, the RIPCAGE trial could meaningfully impact
on the standard of care in cardiac surgical patients.Trial status
Patient recruitment for the study is currently ongoing.Abbreviations
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